RecruitMe Clinical Trial

A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax Combination Therapy
Study of Alvocidib in Patients with Relapsed/Refractory Acute Myeloid Leukemia Following Treatment with Venetoclax Combination Therapy
Sponsor:Tolero Pharmaceuticals, Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS6739
U.S. Government ID:NCT03969420
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

You are being asked to take part in this study because you have acute myeloid leukemia (AML) that has come back after initial treatment (relapsed) with venetoclax combination therapy or because you did not get a complete response from your initial treatment (refractory) with venetoclax combination therapy. The purpose of this research study is to determine the effectiveness (how well something works) and safety of an investigational compound called alvocidib when used either in a combination treatment regimen (low-dose cytarabine) or as a single therapy (alvocidib alone). Investigational means that the Food and Drug Administration (FDA) has not yet approved this treatment as a prescription medicine; it is only available through research studies like this. Alvocidib was previously known as flavopiridol. Alvocidib is an investigational product being developed by Tolero Pharmaceuticals in AML. Cytarabine (also known as Ara-C) is one of the medicines considered as standard of care for the treatment of patients with AML.

Do You Qualify?
Are you 18 years and older?YesNo
Do you have confirmed diagnoses of Acute Myeloid Leukemia?YesNo
Have you ever received Venetoclax in combination with azacytidine or decitabine?YesNo
Submit
Cancel
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162